Micreos is a platform biotech company focused on discovering and developing recombinant antimicrobial enzymes for chronic dermatological disease Micreos is a pre clinical stage pharmaceutical biotech developing enzymes that selectively kill only harmful bacteria while preserving the rest of the microbiome. Our vision is to positively impact patient care while helping global health care systems to address dermatological conditions with high unmet medical need Our unique capability to optimise enzyme therapeutics means that we have already developed an endolysin based investigational enzyme. These antimicrobials are focused on the detrimental impact of Staphylococcus sp. In dermatology. Our team is forging ahead, partnering across medicine, to realise the shared goal of better solutions to combat harmful bacteria in chronic disease.
| Website | http://www.micreosgroup.com |
| Employees | 24 (11 on RocketReach) |
| Founded | 2005 |
| Industry | Biotechnology Research |
Looking for a particular Micreos employee's phone or email?
Martin Vlasaty is the CFO of Micreos.
11 people are employed at Micreos.